Biologics
- Advised Abexxa Therapeutics (antibodies) on all IP matters, including the acquisition by Boehringer Ingelheim
- Advise Boehringer Ingelheim on all IP matters relating to the Abexxa portfolio
- Advise BIOMILQ (cellular agriculture/synthetic biology) on all IP matters, including their $21 million Series A Financing
- Advise Exavir Therapeutics (CRISPR) on all IP matters
- Advised Excision Bio (CRISPR) on all IP matters*
- Advise Hemab (antibodies) on all IP matters
- Advised Mirna Therapeutics (microRNA) on all IP matters, including the $43.75 million IPO and acquisition by Synlogic*
- Advise Nogra (ASOs) on all ASO IP matters
- Advise Nuvig Therapeutics (Fc therapeutics) on all IP matters, including the $47 million Series A financing
- Advise OncoResponse (antibodies; Phase I clinical trials) on all IP matters related to OR2805, including their $40 million Series B financing and $40 million Series C financing
- Advised PDI Therapeutics (antibodies) on all IP matters, including $26 million Series A*
- Advise Treos Bio (peptide-based immunotherapies; Phase II clinical trials) on all US IP matters
- Advise Triumvira (T cell therapies; Phase I clinical trials) on all IP matters, including the $100 million Series A financing
Small Molecules
- Advise Avelas Biosciences (targeted imaging agents; Phase II clinical trials) on all IP matters
- Advise ENB Therapeutics (small molecules; Phase I clinical trials) on all IP matters
- Advise Exavir (small molecules) on all IP matters
- Advise Morphimmune (targeted effector molecules) on all IP matters, including licensing transactions and the $12 million Series A financing
- Advised OncoNano Therapeutics (targeted effector molecules and imaging agents) on all IP matters*
- Advised Pharmacyclics (small molecules) on all IP matters related to HDAC portfolio and its $21 billion acquisition by AbbVie*
- Advise Redesign Science (small molecules) on all IP matters
- Advise Savara Pharmaceuticals (small molecules; Phase III clinical trials) on all IP matters
- Advise Sporos Bioventures (small molecules) on all IP matters
- Advise Tvardi Therapeutics (small molecules; Phase II clinical trials) on all IP matters including the $74 million Series A financing
Venture Capital
- Advise Artis Venture Partners on select IP matters, including the $70 million Series A financing of Delix Therapeutics
- Advise Avalon Bioventures on select IP matters, including formation of Avelas Biosciences and PDI Therapeutics
- Advise Illumina Ventures on select IP matters
- Advise Redmile on select IP matters, including the $70 million Series B financing of Lycia Therapeutics
- Advise Research Bridge Partners on all IP matters, including formation of MorphImmune, Novosteo, and Tuebor Energy
- Advise Sporos Bioventures on select IP matters, including the $14.5 million Series A financing of Asylia Therapeutics and the $15.5 million Series A financing of Stellanova Therapeutics
IPOs, M&As, and Licensing Transactions
- Amylyx Pharmaceuticals in its $190 million IPO
- Atsena Therapeutics in its license negotiations with the University of Florida*
- Lumena Pharmaceuticals in its $260 million acquisition by Shire*
- Seragon Therapeutics in its $1.7 billion acquisition by Roche/Genentech*
- Special Committee of the Board of Directors of NantKwest in the merger of NantKwest and ImmunityBio
Medical Device/Software
- Advised Alleviant Medical (interatrial shunt) on all IP matters*
- Advised Genetesis (software/imaging device) on all IP matters, including $4.5 million Series A financing and $9.2 million Series B financing*
- Advised IntuiTap Medical (image guided spinal tap device) on all IP matters*
- Advised Tearlab (diagnostic device) on all IP matters*
*Denotes experience prior to joining Goodwin.
Professional Experience
Ms. Poulos began practicing in 2007 and was a partner at Wilson Sonsini in San Francisco prior to moving to Goodwin Procter.
Prior to law school, she spent three years engineering knock-out mice as a research associate at Lexicon Genetics, now Lexicon Pharmaceuticals.
